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LIST OF PAPERS 
The present PhD thesis is based on the following five manuscripts published in peer-
reviewed journals including two systematic reviews and three original articles. The 
papers will be referred to by their roman numerals (I-V): 
 
CORTICOSTEROIDS IN MANDIBULAR THIRD MOLAR SURGERY: 
I. Larsen MK, Kofod T, Christiansen AE, Starch-Jensen T. Different Dosages 
of Corticosteroid and Routes of Administration in Mandibular Third Molar 
Surgery: a Systematic Review. J Oral Maxillofac Res. 2018;29:9(2):e1. 
 
II. Larsen MK, Kofod T, Duch K, Starch-Jensen T. Short-term Haematological 
Parameters Following Surgical Removal of Mandibular Third Molars with 
Different Doses of Methylprednisolone Compared with Placebo. A 
Randomized Controlled Trial. J Oral Maxillofac Res. 2020;11(2):e3. 
 
III. Larsen MK, Kofod T, Duch K, Starch-Jensen T. Efficacy of 
methylprednisolone on pain, trismus and quality of life following surgical 
removal of mandibular third molars: a double-blind, split-mouth, randomised 
controlled trial. Med Oral Patol Oral Cir Bucal. 2020;24094.  
 
CHRYOTHERAPY IN MANDIBULAR THIRD MOLAR SURGERY: 
IV. Larsen MK, Kofod T, Starch-Jensen T. Therapeutic efficacy of cryotherapy 
on facial swelling, pain, trismus and quality of life after surgical removal of 
mandibular third molars: A systematic review. J Oral Rehabil. 2019;46:563-
573. 
 
V. Larsen MK, Kofod T, Darvann T, Duch K, Starch-Jensen T. Surgical 
removal of mandibular third molars with or without the use of cryotherapy. 
A single-blinded randomised controlled trial. Clinical and Experimental 





CI Confidence interval 
GCP Good Clinical Practice 
GEE Generalised estimating equation analysis 
ICP Iterated Closest Point algorithm 
MeSH Medical subject heading 
NSAIDs Non-steroidal anti-inflammatory drugs 
OHIP Oral health impact profile 
QoL Quality of life 
RCT Randomised controlled trial 
ROI Region of interest 
SRM3 Surgical removal of mandibular third molar  
T0 Before surgery 
T1 One day after surgery 
T2 Three days after surgery  
T3 Seven days after surgery 
T4 One month after surgery 





The present PhD thesis includes two systematic reviews (paper I and IV) and two 
randomised controlled trials (RCTs) assessing the use of methylprednisolone and 
cryotherapy following surgical removal of mandibular third molar (SRM3) (paper II, 
III and V). 
SRM3 is the most frequently performed surgical procedure in dental practice. 
Pain, restricted mouth opening and facial swelling are well-known and common 
complications following SRM3. Moreover, patients often experience deterioration in 
quality of life (QoL) and sick leave due to pain and facial swelling. Prophylactic 
measures are commonly used to prevent or diminish postoperative sequelae following 
SRM3. The present PhD thesis evaluates the effect of methylprednisolone and 
cryotherapy to reduce postoperative discomfort following SRM3.  
The purpose of paper I was to test the hypothesis of no difference in pain, restricted 
mouth opening, facial swelling and QoL with different doses and administration 
routes of corticosteroids following SRM3. The systematic literature search revealed 
seven studies fulfilling the inclusion criteria. Meta-analysis was not applicable due to 
heterogeneity among the included studies. The hypothesis of no difference in pain, 
restricted mouth opening, facial swelling and QoL with different doses and 
administration routes of corticosteroids could neither be confirmed nor rejected. It was 
therefore concluded that there was a lack of RCTs evaluating the effect on pain, 
restricted mouth opening, facial swelling and QoL with different doses and 
administration routes of corticosteroids following SRM3. 
The purpose of paper II and III was to test the hypothesis of no difference in pain, 
restricted mouth opening, QoL and haematological parameters with different doses of 
methylprednisolone compared with placebo injected into the masseter muscle prior to 
SRM3. The study was designed as a split-mouth, double-blind RCT. Fifty-two 
patients were included involving 104 mandibular third molars, which were allocated 
to one of the following groups: 
• Placebo 
• 20mg methylprednisolone 
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• 30mg methylprednisolone 
• 40mg methylprednisolone 
Pain, restricted mouth opening, QoL and haematological parameters were assessed 
after one day, three days, seven days and one month, respectively. No significant 
difference in pain, restricted mouth opening, QoL and haematological parameters was 
revealed between different doses of methylprednisolone compared with placebo. It 
was therefore concluded that a single dose of methylprednisolone prior to SRM3 does 
not reduce postoperative discomfort. Further studies assessing higher doses of 
methylprednisolone or other varieties of corticosteroids as well as alternative 
administration routes are needed before definitive conclusions can be provided about 
the effect of corticosteroids to diminish discomfort following SRM3. 
Paper IV intended to test the hypothesis of no difference in pain, restricted mouth 
opening, facial swelling and QoL with or without cryotherapy following SRM3. The 
systematic literature search revealed six studies fulfilling the inclusion criteria. Meta-
analysis could not be performed due to heterogeneity among the included studies. The 
hypothesis of no difference in pain, restricted mouth opening, facial swelling and QoL 
with or without cryotherapy could neither be confirmed nor rejected. It was therefore 
concluded that further studies are needed before evidence-based recommendations 
can be provided about the effect of cryotherapy to diminish postoperative discomfort 
and improve QoL following SRM3.  
The purpose of paper V was to test the hypothesis of no difference in pain, 
restricted mouth opening, facial swelling and QoL following SRM3 with 30 minutes 
of continuous cryotherapy compared with no cryotherapy in a single-blinded, split-
mouth RCT. A total of 31 patients involving 62 mandibular third molars were 
included and allocated to 30 minutes of postsurgical cryotherapy or no cryotherapy. 
Pain, restricted mouth opening, facial swelling and QoL were assessed after one day, 
three days, seven days and one month, respectively. No significant difference in pain, 
restricted mouth opening, facial swelling and QoL was revealed between cryotherapy 
and no cryotherapy. It was therefore concluded that 30 minutes of immediate 
continuous cryotherapy following SRM3 does not reduce discomfort compared with 
no cryotherapy. Further studies assessing longer duration of cryotherapy or alternative 
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application methods are needed before definitive conclusions can be provided about 
the effect of cryotherapy to diminish postoperative discomfort following SRM3.  
The conclusions of the present PhD thesis indicate that methylprednisolone and 
cryotherapy does not diminish postoperative discomfort or improve QoL following 
SRM3. However, further studies involving higher doses, other varieties of 
corticosteroids or administration routes as well as longer duration of cryotherapy or 
alternative application methods following SRM3 are needed before definitive 






Nærværende ph.d.-afhandling involverer to systematiske oversigtsartikler (artikel I og 
IV) samt to randomiserede kontrollerede undersøgelser omhandlende anvendelsen af 
methylprednisolon og kryoterapi i forbindelse med kirurgisk fjernelse af 
visdomstænder i underkæben (artikel II, III og V). 
Fjernelse af visdomstænder i underkæben er den kirurgiske procedure, som 
foretages hyppigst i tandlægepraksis. Smerte, nedsat gabeevne og hævelse er 
velkendte komplikationer til kirurgisk fjernelse af visdomstænder. Nedsat livskvalitet 
og sygemelding opleves ligeledes af mange patienter efter fjernelse af visdomstænder 
som følge af smerte og hævelse. Forskellige profylaktiske foranstaltninger anvendes 
derfor ofte med det formål at reducere det postoperative ubehag. Nærværende ph.d.-
afhandling har til formål at undersøge, om methylprednisolon og kryoterapi kan 
nedsætte eller minimere postoperativt ubehag efter kirurgiske fjernelse af 
visdomstænder i underkæben. 
Artikel I havde til formål at teste hypotesen om ingen forskel i smerte, nedsat 
gabeevne, hævelse og livskvalitet efter kirurgisk fjernelse af visdomstænder i 
underkæben med forskellige doser og administrationsveje af kortikosteroider. 
Systematisk litteratursøgning resulterede i syv undersøgelser, der opfyldte 
inklusionskriterierne. Meta-analyse kunne ikke udarbejdes som følge af heterogenitet 
mellem de inkluderede undersøgelser. Hypotesen om ingen forskel i smerte, nedsat 
gabeevne, hævelse og livskvalitet ved forskellige doser og administrationsmåder af 
kortikosteroider kunne hverken be- eller afkræftes. Det blev derfor konkluderet, at der 
er behov for yderligere randomiserede kontrollerede undersøgelser, der vurderer 
effekten på smerte, nedsat gabevene, hævelse og livskvalitet ved anvendelse af 
forskellige doser og administrationsveje af kortikosteroider i forbindelse med 
kirurgisk fjernelse af visdomstænder i underkæben. 
Artikel II og III havde til formål at teste hypotesen om ingen forskel i smerte, 
nedsat gabeevne, livskvalitet og hæmatologiske parametre ved anvendelse af 
forskellige doser methylprednisolon injiceret i musculus masseter sammenlignet med 
placebo i forbindelse med kirurgisk fjernelse af visdomstænder i underkæben. 
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Undersøgelsen blev designet som en sideopdelt, dobbeltblindet randomiseret 
undersøgelse. I alt blev 52 patienter inkluderet involverende 104 visdomstænder i 
underkæben, som blev allokeret til en af følgende grupper: 
• Placebo 
• 20mg methylprednisolon 
• 30mg methylprednisolon 
• 40mg methylprednisolon 
Smerte, gabeevne, livskvalitet og hæmatologiske parametre blev vurderet efter 
henholdsvis en dag, tre dage, syv dage og en måned. Ingen signifikant forskel i smerte, 
nedsat gabevene, livskvalitet og hæmatologiske parametre blev fundet mellem de 
forskellige doser methylprednisolon sammenlignet med placebo. Det blev derfor 
konkluderet, at en enkelt dosis methylprednisolon før kirurgisk fjernelse af en 
visdomstand i underkæben ikke antages at reducere det postoperative ubehag. 
Imidlertid er der behov for supplerende undersøgelser, der anvender højere doser eller 
andre typer af kortikosteroider og administrationsveje, før der kan anbefales endelige 
konklusioner om effekten af kortikosteroider til at mindske postoperativt ubehag efter 
kirurgisk fjernelse visdomstænder i underkæben.  
Artikel IV havde til formål at teste hypotesen om ingen forskel i smerte, nedsat 
gabeevne, hævelse og livskvalitet ved anvendelse af kryoterapi i forbindelse med 
kirurgisk fjernelse af visdomstænder i underkæben. Systematisk litteratursøgning 
resulterede i seks undersøgelser som opfyldte inklusionskriterierne. Meta-analyse 
kunne ikke udarbejdes som følge af heterogenitet mellem de inkluderede 
undersøgelser. Hypotesen om ingen forskel i smerte, nedsat gabeevne, hævelse og 
livskvalitet ved anvendelse af kryoterapi kunne hverken be- eller afkræftes. Det blev 
derfor konkluderet, at der er behov for yderligere undersøgelser, før evidensbaserede 
anbefalinger kan anbefales om virkningen af kryoterapi til at formindske postoperativt 
ubehag og bedre livskvaliteten efter kirurgisk fjernelse af visdomstænder i 
underkæben.  
Artikel V havde til formål at teste hypotesen om ingen forskel i smerte, nedsat 
gabeevne, hævelse og livskvalitet efter kirurgisk fjernelse af visdomstænder i 
underkæben med 30 minutters postoperativ kryoterapi sammenlignet med ingen 
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kryoterapi i en enkeltblindet, sideopdelt randomiseret kontrolleret undersøgelse. I alt 
blev 31 patienter involverende 62 visdomstænder inkluderet og allokeret til 30 
minutters kryoterapi eller ingen kryoterapi. Smerte, nedsat gabevene, hævelse og 
livskvalitet blev vurderet efter henholdsvis en dag, tre dage, syv dage og en måned. 
Der var ingen signifikant forskel i smerte, nedsat gabeevne, hævelse og livskvalitet 
ved anvendelsen af kryoterapi sammenlignet med ingen kryoterapi. Det blev derfor 
konkluderet, at 30 minutters kryoterapi efter kirurgisk fjernelse af en visdomstand i 
underkæben ikke antages at reducere postoperative gener sammenlignet med ingen 
kryoterapi. Imidlertid er der behov for supplerende undersøgelser, der vurderer 
effekten af længerevarende kryoterapi eller alternative applikationsmetoder, før 
kliniske rekommandationer om anvendelsen af kryoterapi til at mindske postoperativt 
ubehag efter kirurgisk fjernelse af underkæbens visdomstænder kan anbefales. 
Konklusionerne i den nuværende ph.d.-afhandling indikerer, at methylprednisolon 
og kryoterapi ikke mindsker postoperativt ubehag eller forbedrer livskvaliteten efter 
kirurgisk fjernelse af visdomstænder i underkæben. Imidlertid er der behov for 
supplerende undersøgelser involverende alternative fabrikater af kortikosteroider, 
højere doser og administrationsveje samt længere varighed af kryoterapi eller andre 
applikationsmetoder i forbindelse med kirurgisk fjernelse af visdomstænder i 
underkæben før evidensbaseret kliniske retningslinjer kan anbefales. 
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Surgical removal of mandibular third molar (SRM3) is the most commonly performed 
surgical intervention in dental clinics. The surgical procedure causes injury to the 
surrounding tissues, which initiates an inflammatory response causing pain, facial 
swelling, restricted mouth opening and deterioration in quality of life (QoL). Several 
prophylactic measures have been described in the literature to prevent or diminish 
postoperative sequelae following SRM3 including non-steroidal anti-inflammatory 
drugs (NSAID), paracetamol, antibiotics, corticosteroids, cryotherapy, laser, local 
compression, platelet-rich fibrin and surgical drains (1–7). Corticosteroids and 
cryotherapy in combination with analgesics are frequently used to lessen 
postoperative sequelae following SRM3 (8–10). However, the optimal dose, 
administration method and duration of treatment are presently unknown.  
Severe pain, restricted mouth opening, facial swelling, affected QoL and sick leave 
are frequently expressed by patients following SRM3, although most of the patients 
usually return to work after one to three days of sick leave (11–13). Complete recovery 
without pain, normal facial physiognomy, habitual range of jaw movements as well 
as eating and speaking ability following SRM3 is usually achieved after four to six 
weeks (11). However, discomfort and sequelae following SRM3 may severely affect 
QoL during the early postoperative period and could even discourage patients from 
seeking further dental treatment (14–18).  
Therefore, from a patient’s point of view, it will be an advantage, if the 
inflammatory response following SRM3 could be diminished or minimised by 





MANDIBULAR THIRD MOLARS 
The most common indications for SRM3 are infection, caries, periodontal diseases, 
orthodontics or prophylactic reasons (12,15). In Denmark, approximately 36,000 
mandibular third molars are removed per year by general dental practitioners or oral 
surgeons.  
Position of mandibular third molars differs and the used technique for removal 
varies from simple extraction to advanced surgical intervention. The position is often 
classified according to Pell and Gregory system as well as Winters classification (19). 
The frequency and severity of postoperative complications following SRM3 is 
generally low including pain, restricted mouth opening, facial swelling, bleeding, 
neurosensory deficiency, alveolitis, delayed healing, infection and damage to 
neighbouring teeth (13,20). Age, gender, compromised medical status, smoking, poor 
oral hygiene, anatomy, length of surgical procedure and experience of the surgeon 
have been associated with increased risk of complications (20). 
SRM3 initiates a long-lasting sequence of healing stages including inflammation, 
epithelialisation, fibroplasia and remodelling. Initially, a vasoconstriction occurs 
followed by a vasodilatation mediated by histamine, kinins and prostaglandins (21). 
The empty tooth socket will be filled with coagulated blood following SRM3. 
Inflammation occurs during the first week, where white blood cells enter the socket 
to remove any debris. Afterwards fibroblasts and capillaries growth into the socket 
(fibroplasia). Migration of the epithelium (epithelialisation) will close the extraction 
alveolus, while osteoclasts accumulate along the crestal bone. The socket will be filled 
with large amount of granulation tissue in the second week and osteoid deposition 
begins along the alveolar bone lining. Complete osteoid healing of the extraction 
socket usually occurs after four to six months (19). Consequently, the inflammatory 
reaction during the first weeks following SRM3 involving pain, restricted mouth 
opening, facial swelling and impaired QoL is a natural consequence of the wound 
healing process.  
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CORTICOSTEROID 
Corticosteroids are steroid hormones produced in the adrenal cortex of vertebrates or 
synthetic analogues, which are used in a variety of conditions ranging from traumatic 
brain injuries to skin diseases (22). Corticosteroids exert an anti-inflammatory 
function including a reduction in vascular dilatation, liquid transudation and oedema 
formation. Corticosteroids inhibit mast cell production and secretion of cytokine, 
kinin and histamine, which facilitates a reduction in dilatation and permeability of 
blood vessels. Furthermore, corticosteroids inhibit synthesis of prostaglandins causing 
an analgesic effect (23,24). Corticosteroids are classified according to their duration 
of action in short, intermediate and long acting (Table 1) (9,22). The effect on the 
inflammatory response appears to be higher, when corticosteroids are administered 
prior to the surgical intervention (25). Consequently, preoperative administration of 
long-lasting corticosteroids seems advisable to diminish the inflammatory response 
following SRM3. 
Corticosteroid Duration of action Anti-inflammatory 
potency 
Equivalent dose 




Prednisolone 4 5mg 
Methylprednisolone 5 4mg 
Dexamethasone Long (>36 hours) 25 0.75mg 
Bethamethasone 25 0.75mg 
Table 1. Duration of action and anti-inflammatory potency of corticosteroids (8). 
Side effects to a single dose of corticosteroids in oral surgery has never previously 
been described (8,26–31). Potential side effects depend on the intensity and duration 
of treatment. Side effects are primarily seen in long-term therapy and very rarely in 
therapies lasting less than five days (32). Contraindications to long-term use of 
corticosteroids are outlined in Table 2. No studies have previously described 
contraindications to a single dose or short-term use of corticosteroids (33).  
Contraindications: Relative contraindications: 
• Active viral or fungal infections 
• Active or untreated tuberculosis 
• Active acne vulgaris 
• Primary glaucoma 
• Acute psychoses or psychotic 
tendencies 
• Hypertension (related to 
mineralcorticosteroid activity) 
• Diabetes mellitus 
• Osteoporosis 
• Myasthenia gravis 
• Active or latent peptic ulcer 
• Acute or long-lasting infections  
Table 2. Contraindications for the use of corticosteroids. 
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The use of corticosteroids to reduce postoperative sequelae following SRM3 are 
well-described (10,34–36). Betamethasone, dexamethasone and methylprednisolone 
are the most frequently used corticosteroids in dentistry (8,26–28,30,37). However, 
the effect on the inflammatory response is inconsistent due to the use of various doses, 
types and administration routes (8,26). Various doses of dexamethasone significantly 
diminish pain, restricted mouth opening and facial swelling independent of the 
administration route (27–29,37,38). Intramuscular or submucosal administration of 
4mg dexamethasone has been compared with placebo disclosing significantly less 
pain as well as lessened restricted mouth opening and facial swelling (27,28). In 
addition, intramuscularly and perorally administration of 8mg dexamethasone have 
revealed similar results (29). Consequently, the effect of dexamethasone on the 
inflammatory responses seems not to be influenced by the administration route (27–
29,37,38). An equivalent dose of dexamethasone significantly diminish restricted 
mouth opening and facial swelling compared with methylprednisolone following 
SRM3 (30,39). Dexamethasone seems therefore to be more potent and effective to 
diminish postoperative sequelae after SRM3 compared with methylprednisolone 
(30,39). Submucosal administration of 40mg methylprednisolone has been compared 
with placebo disclosing significantly less facial swelling and restricted mouth opening 
(40). The results of different doses of methylprednisolone are divergent, and 
assessment of more than two different doses of corticosteroids has never previously 
been investigated (41). 
Administration of corticosteroid causes a higher level of polymorphonuclear 
leukocytes in the circulating blood as a result of increased rate of entrance from bone 
marrow and decreased rate of removal from the vascular compartment. In contrast, 
the number of lymphocytes, eosinophils, monocytes and basophils decreases after 
administration of corticosteroids. A single dose of cortisol results in 70% decrease of 
lymphocytes and 90% decrease of monocytes, occurring four to six hours after 
treatment and persists for approximately 24 hours (42). Cell numbers then rise 24 to 
72 hours after treatment (42). Level of peripheral eosinophils after SRM3 has 
previously been assessed in one study revealing a 50% reduction in the level of 
eosinophils, when hydrocortisone was administered compared with placebo (31).  
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Administration of corticosteroids in conjunction with SRM3 seems to diminish 
pain, restricted mouth opening and facial swelling. However, the optimal 
administration route, fabricate and most effective dose are presently unknown.  
 
CRYOTHERAPY 
Cryotherapy has been defined as the therapeutic use of cold to reduce the 
inflammatory responses due to vasoconstriction (43). Cryotherapy can be used 
continuously or intermittently. Application of an ice pack over the cheek immediately 
following SRM3 is frequently recommended to diminish postoperative sequelae (18). 
No side effects or discomfort of cryotherapy has previously been described in the 
literature (44–46). Application of cryotherapy compared with no cryotherapy in 
conjunction with SRM3 have only been assessed in few RCTs (44,45,47–50). Thirty 
minutes of intermittent cryotherapy every 1.5 hours for 48 hours have demonstrated 
significant less pain and restricted mouth opening compared with no cryotherapy 
following SRM3 (45). However, no significant difference has been revealed with 24 
hours of continuous cryotherapy compared with no cryotherapy (47). Consequently, 
different application methods, duration of treatment time and therapeutic effect have 
been reported following SRM3 with or without intermittent or continuous cryotherapy 
(44–47), which is in accordance with the conclusions of previously published 
systematic reviews (18,51,52). 
In conclusion, application of long-lasting intermittent and continuous cryotherapy 
seems to diminish pain and facial swelling following SRM3. However, prolonged 
cryotherapy could be problematic to implement in an everyday life or dental practise. 
Short-term and immediate application of cryotherapy will therefore be more 
compatible, but RCTs assessing sequelae following SRM3 with short-term 
cryotherapy combined with a jaw bra are missing. Moreover, three-dimensional (3D) 
stereophotography measurements of facial swelling following SRM3 with or without 




The aims of the present PhD thesis were to evaluate the influence of corticosteroid 
and cryotherapy on postoperative sequelae following SRM3. The specific aims were: 
 
• To conduct a comprehensive and systematic literature search to identify 
relevant studies assessing postoperative sequelae following SRM3 in 
conjunction with administration of corticosteroids. 
 
• To evaluate pain, restricted mouth opening and QoL following a single dose 
of methylprednisolone in the masseter muscle prior to SRM3 compared with 
placebo. 
 
• To evaluate the influence of a single dose of methylprednisolone prior to 
SRM3 on haematological parameters including C-reactive protein and 
leucocytes. 
 
• To conduct a comprehensive and systematic literature search to identify 
relevant studies assessing postoperative sequelae following SRM3 in 
conjunction with cryotherapy. 
 
• To evaluate pain, restricted mouth opening, facial swelling and QoL 
following SRM3 with 30 minutes of postoperative cryotherapy compared 






• No difference in pain, restricted mouth opening, facial swelling and 
immediate QoL following SRM3 between different doses and administration 
routes of corticosteroids (I). 
 
• No difference in pain, restricted mouth opening and immediate QoL 
following SRM3 with different doses of methylprednisolone in the masseter 
muscle compared with placebo (II). 
 
• No difference in haematological parameters including haemoglobin, C-
reactive protein and leucocytes following SRM3 with different doses of 
methylprednisolone in the masseter muscle compared with placebo, after 
three days (III). 
 
• No difference in pain, restricted mouth opening, facial swelling and 
immediate QoL following SRM3 with or without postoperative cryotherapy 
(IV).  
 
• No difference in pain, restricted mouth opening, facial swelling and 
immediate QoL following SRM3 with 30 minutes of continuous 








MATERIALS AND METHODS 
Paper I 
Paper I is a comprehensive systematic review following PRISMA guidelines 
including RCTs in humans assessing treatment outcome following SRM3 with the use 
of different doses and/or administration routes of corticosteroids. 
 
Research questions: 




• Restricted mouth opening 
• Facial swelling 




A Medline (Pubmed), Embase and Cochrane Library search was conducted. RCTs 
published in English until 1st December 2017 was included. The search strategy was 
performed in collaboration with a medical librarian utilised a combination of Medical 
subject heading (MeSH) and free text terms.  
 
Inclusion criteria: 
• RCTs in humans 
• A minimum of 20 patients 
 
Exclusion criteria: 
• Studies with insufficient description of patient selection, surgical procedure, 
doses of corticosteroids and administration routes as well as studies 
including medically compromised patients 
 30 
• Studies comparing the effect of corticosteroids with other pharmacological 
therapies or combining corticosteroids with other medications  
 
Paper II and III 
The study was designed as a double-blinded, split-mouth RCT assessing different 
doses of methylprednisolone compared with placebo.  
The study was carried out at the Department of Oral and Maxillofacial Surgery, 
Aalborg University Hospital, Denmark between March 2018 and January 2019. The 
included patients consisted of a population that were scheduled for SRM3 due 
orthognathic treatment of a facial deformity or recruited from Aalborg University 
Hospital’s Facebook profile. Inclusion and exclusion criteria are outlined in Table 3. 
Inclusion criteria: Exclusion criteria: 
• Bilateral symmetrical impacted 
mandibular third molars. 
• Indication for removal of mandibular 
third molars. 
• Age between 18 and 40 years. 
• No indication for removal of 
mandibular third molars. 
• Unilateral mandibular third molar. 
• Infections and inflammatory 
symptoms in the oral cavity at the time 
of surgery. 
• Previous maxillofacial trauma. 
• Craniofacial clefts or syndromes. 
• Systemic bone disease (i.e. arthritis) or 
diabetes mellitus. 
• Active acne vulgaris, viral and fungal 
infections. 
• Psychological disease. 
• Failure to attend follow-up. 
Table 3. Inclusion and exclusion criteria for enrolment in paper II and III. 
The mandibular third molars were randomly allocated into one of the four groups:  
I:  Placebo (isotonic saline solution) 
II:  20mg methylprednisolone 
III:  30mg methylprednisolone  
IV:  40mg methylprednisolone 
A computer-aided randomisation scheme was fabricated by the pharmacy 
including randomisation number and allocation group for each mandibular third 
molar. A trained assistant nurse received the allocation groups and prepared syringes 
containing the different mixture of isotonic saline solution and doses of 
methylprednisolone. All syringes contained 1.05mL of clear liquid. The 
randomisation sheet was kept exclusively at the pharmacy at Aalborg University 
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Hospital until the study was unblinded. The patients, surgeon, dental assistant and 
assessor were blindfolded regarding the allocation group and solution of syringes.  
Methylprednisolone was used in the present study instead of dexamethasone or 
other corticosteroids, as methylprednisolone is the only buyable corticosteroid in 
Denmark for intramuscular injection following SRM3. 
 
Paper IV 
Paper IV is a comprehensive systematic review following PRISMA guidelines 








• Restricted mouth opening 
• Facial swelling 




A Medline (Pubmed), Embase and Cochrane Library search was conducted 
supplemented by a thorough hand-search page by page of relevant journals. RCTs 
published in English until 17th of July 2018 were included. The search strategy was 
performed in collaboration with a medical librarian utilised a combination of MeSH 
and free text terms.  
 
Inclusion criteria: 
• RCTs in humans 








The study was designed as a single-blinded, split-mouth RCT assessing cryotherapy 
in conjunction with SRM3.  
The study was conducted at the Department of Oral and Maxillofacial Surgery, 
Rigshospitalet, Copenhagen University Hospital, Denmark between March and May 
2019. Included patients were scheduled for SRM3 due orthognathic treatment of a 
facial deformity. Inclusion and exclusion criteria are outlined in Table 4. 
Inclusion criteria: Exclusion criteria: 
• Bilateral symmetrical impacted 
mandibular third molars. 
• Indication for removal of mandibular 
third molars. 
• Age between 18 and 40 years. 
• No indication for removal of 
mandibular third molars. 
• Unilateral mandibular third molar. 
• Infections and inflammatory 
symptoms in the oral cavity at the time 
of surgery. 
• Previous maxillofacial trauma. 
• Craniofacial clefts or syndromes. 
• Systemic bone disease (i.e. arthritis) or 
diabetes mellitus. 
• Active acne vulgaris, viral and fungal 
infections. 
• Psychological disease. 
• Failure to attend follow-up. 
Table 4. Inclusion and exclusion criteria for enrolment in paper V. 
The impacted mandibular third molars were randomly allocated to:  
I:  No cryotherapy 
II:  30 minutes of postoperative continuous cryotherapy with a jaw bra 
A computerised random number software (http://www.randomization.com, date: 
26th December 2018) was used to randomise the mandibular third molars into 
cryotherapy or no cryotherapy. The software was used to randomly allocate the 
patients into two groups. Sealed envelopes were used to keep the numbers, and every 
patient opened one envelope with a specific number. An assistant nurse received the 
number and combined it with the randomisation sheet to allocate the mandibular third 
molars into one of the two groups. The randomisation sheet was kept exclusively by 
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the nurses at the Department of Oral and Maxillofacial Surgery, Rigshospitalet, 
Copenhagen University Hospital, Denmark, until the study was unblinded. 
The surgeon and assessor were blindfolded regarding the postoperative 
intervention involving cryotherapy or no cryotherapy. The assistant nurse placed a 
jaw bra with a cold gel pack immediately following SRM3 and removed the jaw bra 
after 30 minutes, before postoperative precautions were explained to the patients.  
 
ETHICAL CONSIDERATION 
Approval to conduct the studies in paper II, III and V were obtained from the Research 
Ethics Committee and the Danish Data Protection Agency. The studies were 
performed in accordance with the Declaration of Helsinki II and Consolidated 
Standards of Reporting Trials (CONSORT) statement (53). In addition, paper II and 
III was approved by the Danish Health and Medicines Authority and performed in 
accordance with Good Clinical Practice (GCP). 
Potential candidates were given verbal and written information at a clinical visit 
prior to the surgical procedure. Written informed consent was obtained from every 
patient before enrolment. Participation was voluntary and patients could at any given 
time withdraw from the study. The confidentiality of information and anonymity of 
all patients were respected. Data was stored and analysed in a computer in accordance 
with guidelines from the Danish Data Protection Agency and GCP. Authors and health 
personnel involved in the study disclosed any financial or personal relationship with 
people or organisations that could inappropriately influence their work. The studies 
did not expose included patients to additional risks compared with standard procedure.  
 
SURGICAL PROCEDURE 
Paper II, III and IV 
SRM3 was performed in local anaesthesia by the same surgeon (MKL) using a 
standard technique. All patients received prophylactic analgesics including 400mg 
ibuprofen and 1,000mg paracetamol, one hour before surgery. 
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In paper II and III, injection of methylprednisolone or placebo was performed 
immediately after application of local anaesthesia. The assistant nurse prepared the 
selected solution of methylprednisolone or placebo without knowledge to the surgeon, 
dental assistant or patient.  
An incision from the anterior border of the ascending ramus of the mandible to the 
distal part of the lower first molar was performed. The mucosal flap was elevated and 
the bone around the mandibular third molar was removed with a round burr under 
irrigation with 0.9% saline solution. If necessary, the mandibular third molar was 
sectioned with a fissure bur before the tooth was removed. The extraction socket and 
surrounded bone was irrigated with 0.9% saline solution, and the surgical site was 
sutured (4-0 Vicryl Rapide®, Ethicon, Johnson and Johnson, Germany). 
 
Fig. 1: Clinical photos of the procedure for surgical removal of one mandibular third molar. 
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In paper V, the assistant nurse placed a jaw bra containing a refreezable, cold gel 
pack (Soft Stretch Jaw Bra, Cool Jaw, Palmer, US) for 30 minutes following SRM3, 
if the third molar was allocated to cryotherapy (Fig. 2).  
    
Fig. 2: Clinical photos of a patient wearing a jaw bra. 
All patients received standard postoperative instructions including mouth rinse 
with 0.12% chlorhexidine three times a day, 400mg of ibuprofen three times a day 
and 1,000mg paracetamol four times a day. Sutures were removed 7 days 
postoperatively.  
 
OUTCOME MEASURES  
Paper II, III and V 
Baseline measures were obtained before surgery (T0) and compared with 
postoperative assessments after one day (T1), three days (T2), seven days (T3) and 
one month (T4). Following outcome measures were evaluated (Table 5): 
Paper II and III: 
• Pain 
• Restricted mouth opening 
• Immediate QoL 




• Restricted mouth opening 
• Facial swelling 

















X X X X X 
Restricted 
mouth opening 
X  X X X 
Facial swelling  
 
X  X X X 
Quality of life 
 
X   X X 
Haematological 
parameters 
X  X   
Complications 
 
X  X X X 
Table 5. Outcome measures and time plan.  
 
Pain 
Pain was evaluated using a visual analogue scale (VAS) obtained preoperatively (T0) 
and compared with postoperative measurements at T1, T2, T3 and T4. Patients were 
carefully instructed in the use of a 100-mm VAS scale with 0 indicating no pain and 
100 indicating worst imaginable pain. Patients marked on a line the point that they 
felt represented their pain level. VAS score was measured to the nearest mm using a 
ruler from left to the point marked by the patient. 
 
Restricted mouth opening 
Restricted mouth opening was measured as the maximum distance (mm) between 
upper and lower incisal edges. Baseline measurements were obtained preoperatively 
(T0) and compared with postoperative measurements at T2, T3 and T4. 
 
Facial swelling 
The facial morphology was delineated using a 3D optical scan (David SLS-3 3D 
scanner, DAVID Vision Systems, Germany) obtained preoperatively (T0) and 
compared with postoperative measurements at T2 and T3. Patients were positioned 
one meter from the 3D optical scanner in an upright chair with closed mouth, relaxed 
facial expression and adequate head support. The position of the 3D optical scanner 
and the chair was secured in a uniform position valid for all scans. Straight laser 
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lighters were used to standardise the location of the head in a uniform and reproducible 
position. The laser line followed the frankfurter horizontal plane (Fig. 3).  
   
Fig. 3. Illustration of computer, 3D scanner (projector and camera) and patient. 
DAVID-4-PRO software (DAVID Vision Systems, Germany) was used to capture 
the 3D optical scans and convert the scans to STL-files, which were transferred to 
Landmarker (Software, Landmarker 2.0.6, Denmark) (54). The volumetric difference 
in the facial morphology between T0 was compared with T2 and T3 using Landmarker 
and template matching technique (55–57). A recent contribution applying a similar 
philosophy to calculate facial volume has recently been published (58).  
The volume Vs of facial swelling was defined as the volume (in cm3) of the 3D 
space located between two face surfaces within a swelling region s. The region of 
facial swelling was defined as a user-defined region of interest (ROI) in the face, 
where Vs was to be calculated. The method was devised in such a way that Vs could 
be monitored in the same swelling region over time and in every subject. A swelling 
region on an artificially created 3D template face was drawn and the template was 
subsequently deformed to the shape of each scan, thereby transferring the swelling 
region to each scan (Fig. 4). This process assured that a portion of a subject scan 
corresponding to the swelling region would have detailed point correspondence with 
the swelling region of all other subject scans.  
An outline of the swelling region was drawn on the template face surface (Fig. 4a-
b), and six anatomical landmarks (Fig. 4a) visible on both the template face surface 
and the T0 surface were selected and pointed out by the assessor on both the template 
surface and the T0 surface. A sub-region T0,sub of the T0 surface, which was not 
expected to be affected by the treatment (a region where only minimal change would 
occur over time) was selected at the forehead and bridge of nose. The Iterated Closest 
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Point algorithm (ICP) was used to spatially align all subsequent scans in the same 
subject, Ti, to T0,sub (59). A similarity transform was applied using the six landmarks 
obtained to bring the swelling region stemplate in the template to the general location of 
the swelling regions si in the T0 scan and all subsequent scans (Ti). The stemplate was 
further deformed to each of the si regions by moving each point in stemplate to the closest 
surface location on si. This last step established detailed point correspondence 
between all the si scans. For each triangle in si, the distance to the corresponding 
triangle in s0 was calculated. A sign was added to the distance depending on whether 
s0 was inside (positive sign, swelling) or outside (negative sign, shrinkage) of s0. The 
result was a number of m distance maps (an example is shown in Fig. 4c-e). For each 
triangle in s0, a polyhedron (pentahedron, skew triangular prism) with five faces was 
created by connecting each of its three vertices with the corresponding vertices in si, 
forming a small volume element, and its volume v was calculated (Fig. 4c-d). The 
volume of the swelling region was the sum of all the volume elements: Vsi=sum(vj), 
where j counted the triangles in s. Thereby, the volumetric changes in facial 
morphology were measured. 
 
Fig. 4: Illustration of the measurement process of facial swelling. a) The template face scan with the 
swelling region (white outline) and six alignment landmarks (red spheres). b) Swelling region shown as 
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wireframe. c) Swelling region in an example subject, colour coded according to distance in mm between 
surface at T0 and T2. d) Swelling region in the same example subject, colour coded according to distance 
in mm between surface at T0 and T3. e) Histograms of the distances displayed in figures c) and d). Solid 
curve: T2, Dashed curve: T3.  
The accuracy and precision of the 3D scanner was assessed before the described 
study was initiated in two pilot studies. A total of 40 scans of a mannequin head were 
compared with a reference scan of the same mannequin head, which was based on 
averaging 30 scans of a mannequin head using a 3dMDhead.u (3dMD.com, Atlanta, 
GA, USA) full head scanner. The distance between the reference and each of the 40 
scans was calculated at each surface point after each of the 40 scans had been spatially 
aligned with the reference using the ICP algorithm (59). Histograms of the distances 
were created, and corresponding mean and standard deviation of the distances were 
reported as a measure of accuracy and precision of the David SLS-3 3D scanner. 
Moreover, 3D scans of eight artificial swellings were compared with reference scans 
of the same swellings. In order to validate the method of swelling volume calculation, 
artificial swellings were created by applying silicone material (Coltène President 
Putty, Coltène Whaledent AG, Switzerland) to the mannequin head. The silicone 
material was applied in realistic swelling shapes on the mannequin head and scanned 
in the David SLS-3 3D scanner as well as in a cone beam computed tomography 
scanner (Planmeca ProMax 3D Max, Planmeca OY, Finland) with voxel resolution 
0.4, 0.4, 0.4mm. The silicone material had a different computed tomography value 
than the mannequin head and could thus be segmented by intensity thresholding. Eight 
different artificial swellings were created and scanned in both devices and volumes 
were calculated and compared. In order to determine the threshold parameter for the 
cone beam computed tomography segmentation, an object of known dimensions (a 
Lego Duplo brick, The Lego Group, Denmark) (Fig. 5a) was covered in silicone 
material and scanned in the cone beam computed tomography scanner. The silicone 
material was segmented in the resulting images using different intensity thresholds, 
each time measuring the inside width of the silicone shape corresponding exactly to 
the width of the Duplo brick. The optimal threshold was determined by linear 
regression in a plot of threshold versus measured width (Fig. 5b).  
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Fig. 5: Determination of optimal cone beam computer tomography intensity threshold for segmentation of 
silicone material. a) Image slice through cone beam computer tomography scan of a Lego Duplo brick 
covered with silicone material. b) Plot of the inside width of silicone material encapsulating the Lego Duplo 
brick as a function of cone beam computer tomography intensity threshold. Solid line is regression line 
through the points shown. Dash-dottet line indicates actual width of the Lego Duplo brick as measured by 
callipers.  
 
Quality of life 
Immediate QoL was evaluated by oral health impact profile-14 (OHIP-14). 
Instructions for completing OHIP-14 were explained before patients completed 
OHIP-14 by themselves, to prevent being influenced by the assessor’s opinions and 
wills. OHIP-14 was filled-out before surgery (T0) and compared with OHIP-14 at T3 
and T4. The response format of OHIP-14 was as follows: All the time=4; Very 
often=3; Fairly often=2; Sometimes=1; Never=0. The OHIP-14 score was calculated 
as a sum of all 14 questions ranging from 0 to 56, with higher scores indicating poorer 
oral health related QoL.  
 
Haematological parameters 
Blood samples were obtained by a medical laboratory technologist at Aalborg 
University Hospital, Denmark. Blood samples were collected from the patients before 
(T0) and three days (T1) after SRM3 with no regard to time of the day, physical 
activity or fasting. A total of 8mL of whole blood was collected from the cubital vein. 
Complete haemogram test of the blood samples was conducted within two hours. 
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Level of haemoglobin (mmol/L), leucocytes (counts x 109/L), neutrophils (counts x 
109/L), eosinophils (counts x 109/L) and C-reactive protein (counts/L) were analysed.  
 
Surgical and postoperative complications 
Complications were registered at T0, T2, T3 and T4. 
 
STATISTICAL ANALYSIS 
Paper I and IV 
No meta-analyses could be performed due to considerably heterogeneity among the 
included studies i.e., different study designs, observation periods, outcome measures, 
types of corticosteroids and type and duration of cryotherapy. 
 
Paper II, III and V 
Power calculation 
To ensure adequate power (paper II, III and V), a sample size was made using 
Clincalc.com (http://clincalc.com/stats/samplesize.aspx, assessed 9th March 2017). 
The sample size was determined by pain assessment using an expected difference of 
20mm in VAS score between placebo and treatment on the first postoperative day 
with a statistical power of 0.80 and an alpha value of 0.05. Based on sample size 
calculation and to compensate for possible dropouts and covariates, the sample size 
was increased to 26 and 31 mandibular third molars in paper II, III and V.  
 
Analyses of results 
Data management and statistical analyses were performed using Excel (version 2013, 
Microsoft, Redmond, Washington, USA) and R (version 3.6.1, Missouri, USA).  
Anatomical positions of mandibular third molars were presented as counts and 
percentage on each treatment group. The time of surgery was presented with mean, 
standard deviation, minimum and maximum.  
Mean difference in pain, restricted mouth opening, facial swelling, QoL and 
haematological parameters were analysed with a generalised estimating equation 
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analysis (GEE analysis) for repeated observations. Missing observations in outcome 
variables were assumed to be missing randomly. The estimated mean value for pain, 
restricted mouth opening, facial swelling and QoL were expressed with a 95% 
confidence interval (CI). P values of less than 0.05 were considered significant. The 




The main results of the studies (paper I-V) are presented below. 
 
Paper I 
Seven studies fulfilling inclusion and exclusion criteria were included for analysis. 
The PRISMA flow diagram presents an overview of the selection process (Fig. 6). 
 
Fig. 6. PRISMA flow diagram demonstrating the results of the systematic literature search. 
 
Different administration routes or doses were assessed in one or four studies 
(29,40,60–62), while different doses and administration routes of corticosteroids were 
assessed in two studies (63,64).  
The optimal dose and administration route of corticosteroids for diminishing 




Paper II and III 
Fifty-two patients (16 men and 36 female) with a mean age of 25.9±6 years (range 
18-39) were included for statistical analysis. One patient dropped out during the 
inclusion period and was replaced by another patient. There were no statistically 
significant differences between the groups with regard to smoking, anatomical 
position of mandibular third molars and time of surgery (Table 6). The mean surgical 
time was 9.42 minutes (±5.18). Patients underwent surgical removal of one 
mandibular third molar, while the other mandibular third molar was removed after 
58.8 days (range 8-157). The study was unblinded 13th of May 2019. 










Sex, n (%) Male 8 (30.8) 8 (30.8) 8 (30.8) 8 (30.8) 32 (30.8) 
 Female 18 (69.2) 18 (69.2) 18 (69.2) 18 (69.2) 72 (69.2) 












































No 24 (92.3) 24 (92.3) 22 (84.6) 24 (92.3) 94 (90.4) 



























































































































P&G, Pell & Gregory; n, number of wisdom teeth; Q1, first quartile; Q3, third quartile; sd, standard 
deviation 
Table 6. Baseline characteristics, anatomical position of mandibular third molars and time of surgery.  
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Postoperative instructions were followed by all patients, and none of the patients 
needed additional prescriptions of analgesics. Facial swelling, discomfort, tenderness 
and halitosis were reported sporadically. Postoperative bleeding occurred in two 
patients (1.9%). The bleeding was sufficient treated with supplementary sutures and 
compression. Twenty-two patients (21.1%) had postoperative antibiotics prescribed 
due to a combination of major swelling, pus, increased body temperature and sore 
lymph nodes. Distribution of infection among the four groups was equal with no 
significant difference (P=0.676). None of the patients complained of discomfort or 
complications related to blood samples. No serious postoperative complications or 
neurosensory disturbances were observed. 
 
Pain 
There were no significant differences in VAS score of pain between different doses 
of methylprednisolone compared with placebo at any time point (Fig. 7).  
A significant higher VAS score of pain was seen in patients with increased age 
after seven days and one month (P<0.05). In addition, males presented a significant 
higher VAS score of pain compared with females after one month (P<0.05).  
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Fig. 7. Boxplot illustrating the variability of VAS score of pain between different doses of 
methylprednisolone and placebo. 
 
Restricted mouth opening 
There were no significant differences in restricted mouth opening between different 
doses of methylprednisolone compared with placebo at any time point (Fig. 8). 
A significant difference was assessed in restricted mouth opening between 
smokers and non-smokers after three days and seven days (P<0.05). A significant 
difference in restricted mouth opening was seen with an increased time of surgery 
after three days (P<0.05).  
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Fig. 8. Boxplot illustrating the variability of restricted mouth opening between different doses of 
methylprednisolone and placebo. 
 
Quality of life 
There were no significant differences in immediate QoL between different doses of 
methylprednisolone compared with placebo at any time point (Fig. 9). In each group, 
there were significant differences in the sum of OHIP-14 score between T0 and T3 
(P<0.05) indicating impaired QoL after seven days.  
A significant difference in OHIP-14 score was observed with an increased age 
after seven days (T3) (P<0.05), indicating impaired QoL with increased age.  
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There were no significant differences in the level of haemoglobin between T0 and T1 
with different doses of methylprednisolone compared with placebo at any time point 
(Fig. 10). 
 
Fig. 10. Boxplot illustrating the variability of haemoglobin (mmol/L) between different doses of 
methylprednisolone and placebo. 
There were no significant differences in the level of total leucocytes, neutrophils 
and eosinophils between different doses of methylprednisolone compared with 
placebo at any time point (Fig. 11). The mean level of total leucocytes and neutrophils 
increased in all groups, whereas the mean level of eosinophils decreased in all groups. 
A significant difference in the level of eosinophils was seen between T0 and T1, when 
the results were adjusted for age (P=0.05) revealing a larger reduction in level of 
eosinophils at T1 with increasing age. However, no significant differences in the level 
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of total leucocytes, neutrophils and eosinophils were seen, when the results were 
adjusted for sex, smoking and time of surgery. 
 
Fig. 11. Boxplot illustrating the variability of leucocytes (counts x 109/L) between different doses of 
methylprednisolone and placebo. 
There were no significant differences in the level of C-reactive protein between 
20mg methylprednisolone and 40mg methylprednisolone compared with placebo 
between T0 and T1. However, mean level of C-reactive protein was significantly 
decreased with 30mg methylprednisolone compared with placebo (P<0.05) between 
T0 and T1 (Fig. 12). A significant difference in the level of C-reactive protein was 
observed between smokers and non-smokers (P<0.05) at T1 indicating that smokers 
have a lower increase in the level of C-reactive protein compared with non-smokers. 
 
Fig. 12. Boxplot illustrating the variability of C-reactive protein (counts/L) between different doses of 







Six RCTs fulfilling the inclusion and exclusion criteria were included for analysis. 
The PRISMA flow diagram presents an overview of the selection process (Fig. 13). 
 
Figure 13. PRISMA flow diagram demonstrating the results of the systematic literature search. 
 
Continuous cryotherapy and intermittent cryotherapy were each assessed in three 
studies (44,45,48–50,65). Time and device for cryotherapy varied between the studies 
from 20 minutes to 24 hours. 
The optimal application methods and duration of cryotherapy for diminishing 
postoperative sequelae in mandibular third molar surgery could not be clarified.  
 
Paper V 
Thirty-one patients (14 men and 17 female) with a mean age of 22.7±4.6 years (range 
18-35) were included for statistical analysis. One patient was lost during follow-up 
and was replaced by another patient. There were no statistically significant differences 
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third molar and time of surgery (Table 7). The mean surgical time was 7.0 minutes 
(±3.7). The study was unblinded 9th of May 2019.  























































Time of surgery 
(minutes) 
mean (sd)  
median  
[Q1, Q3]  
min 
max 
7.39 (4.28)  
6.00  
[5.00, 9.00]  
3.00  
20.00 
6.68 (3.05)  
6.00  






7.75] 3.00  
20.00 
P&G, Pell & Gregory; n, number of wisdom teeth; Q1, first quartile; Q3, third quartile; sd, standard 
deviation 
Table 7. Baseline characteristics, anatomical position of mandibular third molars and time of surgery. 
Postoperative instructions were followed by all patients. Swelling, discomfort, 
tenderness and halitosis were reported sporadically. Postoperative antibiotics were 
prescribed to five patients (6.2%) due to a combination of discomfort, pus, moderate 
to major swelling, increased body temperature and sore lymph nodes. Additional 
complications were not observed. 
 
Pain 
There were no significant differences in VAS score of pain between cryotherapy and 
no cryotherapy at any time point (Fig. 14).  
However, a significant higher VAS score was seen in males compared with 
females after one month (T4) (P<0.05).  
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Fig. 14. Boxplot illustrating the variability of VAS score of pain between cryotherapy or no cryotherapy. 
 
Restricted mouth opening 
There were no significant differences in restricted mouth opening between 
cryotherapy and no cryotherapy at any time point (Fig. 15). 
A significant decrease in mouth opening was seen with increased time of surgery, 
after three days (T2) and seven days (T3) (P<0.05).  
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Fig. 15. Boxplot illustrating the variability of mouth opening between cryotherapy and no cryotherapy. 
 
Facial swelling 
There were no statistically significant differences between the two treatment 
modalities at any time point (Fig. 16). However, a tendency to lessened facial swelling 
was observed with no cryotherapy compared with cryotherapy.  
 




Accuracy and precision of David SLS-3 3D scanner 
David SLS-3 3D scanner was highly accurate, reliable and precise during scanning of 
a static object, when comparing the difference between volumes. The mean and 
standard deviation of the mean distance histogram was 0.000±0.037 (Fig. 17). The 
mean and maximum of the differences between volume measurements carried out 
using the two modalities (Vcone beam computer tomography–Vsurface) were -0.20cm3 and 
0.73cm3, (n=8), (P=0.63), respectively, while the correlation between them was 0.98 
(95% CI [0.92;1.00]) (Fig. 18).  
 
Fig. 17. Validation of the David SLS-3 3D scanner. a) The mean mannequin reference face. b) Histograms 
of distances between each of the 40 mannequin face surfaces and the reference. 
 
Fig. 18. Validation of swelling volume calculation. a) Mannequin with artificial swelling. b) Segmented 
swelling from cone beam computer tomography scan. c) Plot of volumes of 8 artificial swellings calculated 
from cone beam computer tomography (x-axis) and surface scans (y-axis). Solid line is regression line 
through the 8 points shown; dashed line represents the line of exact correspondence. 
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Immediate quality of life 
There were no statistically significant differences in immediate QoL between 
cryotherapy and no cryotherapy at any time point (Fig. 19). However, females 
registered a significantly higher OHIP-14 score compared with males after one month 
(T4) (P<0.05) indicating impaired QoL.  
 





The objective of the dissertation was to investigate the influence of different doses of 
corticosteroids and cryotherapy on postoperative sequelae following SRM3. Two 
systematic reviews were conducted to clarify the current knowledge about the use of 
corticosteroid and cryotherapy in mandibular third molar surgery disclosing that the 
optimal dose of corticosteroid as well as application method and duration of 
cryotherapy are presently unknown. In an attempt to add new knowledge, two RCTs 
assessing sequelae following SRM3 with different doses of methylprednisolone or 30 
minutes of immediate cryotherapy were conducted. 
In the following sections, results of the present RCTs are discussed in relation to 
pain, restricted mouth opening, facial swelling, QoL and haematological parameters. 
Finally, methodological considerations and limitations of the studies are emphasised. 
 
PAIN 
Pain is an unpleasant sensation induced by noxious stimuli that are sensed by nerve 
endings of nociceptive neurons (66). VAS, numerical rating and verbal rating scales, 
faces pain scale-revised, self-administered questionnaires and consumptions of 
analgesics are frequently used to assess pain score following SRM3 (15,45,48,67,68). 
VAS, numerical rating scale, verbal rating scale and faces pain scale-revised are 
considered as valid tools for pain assessment (68,69). However, pain is a subjective 
and individual sensation, and the overall validity is therefore difficult to assess (69). 
In generally, patients have different perceptions of pain, which is influenced by 
various factors such as time of surgery, type and intensity of noxious stimuli, genetics, 
age, gender, previous dental experience and culture (70–74). Moreover, consumption 
of anti-inflammatory medications and antibiotics reduce postoperative pain, why 
inconsistent intake of medication influences the perception of pain score following 






Pain relief following administration of corticosteroids is due to an inhibitory effect on 
prostaglandin formation and diminished facial swelling (77). However, the optimal 
dose of corticosteroids and administration route for diminishing pain following SRM3 
were not clarified in the systematic review (paper I) (41). Moreover, higher doses of 
corticosteroids seemed not to proportionally diminish pain following SRM3 (41). 
However, methylprednisolone has demonstrated significantly less pain compared 
with dexamethasone following SRM3. Though, the dose of methylprednisolone 
(40mg) was higher than dexamethasone (approximate: 32mg methylprednisolone) 
(40). 
The included studies of the systematic review (paper I) measured pain with VAS. 
In addition, some of the included studies supplemented VAS score of pain with 
consumption of analgesics (40,60,62). However, type and dose of analgesics varied 
among the included studies, which definitely influenced the VAS score of pain and 
masked the effect of corticosteroids. The optimal study design should therefore 
include identical consumption of analgesics in order to determine the actual effect of 
corticosteroids in pain relief.  
Paper II revealed no significant differences in VAS score of pain following SRM3 
with different doses of methylprednisolone compared with placebo at any time points 
(78). VAS score of pain was significantly increased with higher age, which is in 
accordance with previous studies (71,72). Furthermore, males presented with a 
significant higher VAS score compared with females after one month. Postoperative 
analgesics were prescribed to all patients, but the actual consumption of analgesics 
was not recorded. Consequently, the effect of methylprednisolone on pain relief could 
therefore have been influenced by inconsistent need for analgesics. Further studies 
assessing higher doses of methylprednisolone or other corticosteroids with identical 
consumption of analgesics are therefore needed before definitive conclusions can be 
provided about the beneficial use of corticosteroids in pain relief following SRM3.  
 
Cryotherapy 
Pain relief following cryotherapy is due to slowing the conduction of nerve signals 
(79). However, the optimal application method and duration time for diminishing pain 
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following SRM3 were not clarified in the systematic review (paper IV) (78). 
Continuous cryotherapy for 45 minutes and intermittent cryotherapy for 30 minutes 
in 24 and 48 hours have shown significant less pain compared with no cryotherapy 
following SRM3 (45,48,49), whereas 24 hours of continuous cryotherapy has shown 
no significant reduction in pain compared with no cryotherapy (47). Moreover, 
continuous cryotherapy for 45 minutes with the use of a Hilotherm device has 
demonstrated significant reduction in VAS score of pain compared with conventional 
cryotherapy (cool compresses) following SRM3 (80). Consequently, the application 
methods and duration time seems to influence the therapeutic effect of cryotherapy on 
pain relief. However, the clinical impact of pain relief must necessarily be adapted to 
the patient's daily life and dental practice, which is hampered by 48 hours intermittent 
cryotherapy or regular use of a Hilotherm device following SRM3. 
Paper V disclosed no significant differences in VAS score of pain following SRM3 
with 30 minutes continuous postoperative cryotherapy on the check compared with 
no cryotherapy (paper V) (81). A jaw bra with a refreezable gel pack were used since 
it is cheap, easy to adapt to dental practice and does not significantly affect the 
patient's daily life. However, no beneficial effect on pain relief was achieved. Anti-
inflammatory medication inhibits production of prostaglandins and thereby reducing 
pain and inflammation. Postoperative anti-inflammatory medication (Ibuprofen) was 
prescribed to all patients, but the actual consumption of anti-inflammatory medication 
was not recorded. Consequently, the effect of cryotherapy on pain relief could 
therefore have been influenced by dissimilar consumption of anti-inflammatory 
medication. Moreover, the use of a jaw bra for a longer period could have improve 
the effect on pain relief. Further studies assessing the therapeutic effect of cryotherapy 
should therefore include different time periods with identical consumption of 
analgesics before definitive conclusions can be provided about the beneficial use of 
cryotherapy in pain relief following SRM3. 
 
RESTRICTED MOUTH OPENING 
Restricted mouth opening is a decrease in mouth opening, also known as trismus, 
which can occur in relation to oral surgery, pain, infection, temporomandibular 
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disorders, radiotherapy for head or neck cancer, trauma or neoplastic conditions (82). 
The severity of restricted mouth opening following SRM3 is often related to the 
surgical difficulty and length of treatment time (83). Highest level of restricted mouth 
opening following SRM3 is usually observed on the first postoperative day with a 
subsequently improvement (83). Restricted mouth opening interferes with patients’ 
ability to eat, speak and maintaining oral hygiene (82). Linear measurement of 
maximal interincisal distance with a ruler or a Vernier calliper is a simple, reliable, 
reproducible and validated method, which has previously been used for measurements 
of mouth opening following SRM3 (44,45,49,50,65).  
 
Corticosteroids 
Diminished restricted mouth opening following SRM3 with administration of 
corticosteroids is presumable due to reduced facial swelling and lessened pain (40,64). 
A previous study has demonstrated that preoperative submucosal injection of 40mg 
methylprednisolone significantly diminishes restricted mouth opening compared with 
placebo (67). However, the optimal dose of corticosteroids and administration route 
for improving mouth opening following SRM3 were not clarified in the systematic 
review (paper I) (66). Moreover, a higher dose of corticosteroids seems not to 
proportionally diminish restricted mouth opening (41). The included studies of the 
systematic review revealed considerably heterogeneity involving different doses and 
fabricates of corticosteroids, administration routes and observation periods. 
Consequently, an association between administration of corticosteroids and improved 
mouth opening following SRM3 could not be clarified. 
Paper II revealed no significant differences in restricted mouth opening following 
SRM3 with different doses of methylprednisolone compared with placebo at any time 
points (70), which is in agreement with previous studies (60,62). Smokers disclosed 
significantly increased restricted mouth opening compared with non-smokers after 
three and seven days, which is in accordance with previous studies (12,84). However, 
the smoking habit was not categorised and ranged from rarely to more than 20 
cigarettes daily, which interferes with the reliability of the present result. Moreover, 
no significantly difference in mouth opening following SRM3 has previously been 
reported among smokers compared with non-smokers (85). A significant association 
 61 
between increased time of surgery and postoperative deterioration of mouth opening 
was revealed in paper II, which is in accordance with previous studies (12,86). 
Infection can cause restricted mouth opening following SRM3 (83). Though, there 
was no correlation between restricted mouth opening and infection in paper II (87). 
Assessment of restricted mouth opening following SRM3 seems to be influenced by 
various parameters. Consequently, a uniform and comparable study design is 
therefore mandatory to be able to assess whether corticosteroids prevent impaired 
mouth opening following SRM3.  
 
Cryotherapy 
Diminished restricted mouth opening following SRM3 with cryotherapy is probably 
due to decreased facial swelling, tissue oedema and haematoma (79,88,89). The 
therapeutic effect of cryotherapy depends on the application methods, duration of 
treatment time, temperature and depth of the subcutaneous fat (79,88,89). However, 
the optimal application method and duration time of cryotherapy for diminishing 
restricted mouth opening following SRM3 were not clarified in the systematic review 
(paper IV) (70). Intermittent cryotherapy for 30 minutes in 24 hours have 
demonstrated significant diminished restricted mouth opening compared with no 
cryotherapy following SRM3 (49), whereas continuous cryotherapy for 24 hours have 
shown no significant difference in restricted mouth opening compared with no 
cryotherapy (47). 
Paper V disclosed no significant differences in restricted mouth opening following 
SRM3 with 30 minutes continuous postoperative cryotherapy on the check compared 
with no cryotherapy (81). However, the temperature of the refreezable gel pack was 
not standardised and thickness of the subcutaneous fat varied among the included 
patients. Moreover, consumption of anti-inflammatory medications was not 
registered. A considerably homogenous patient sample and study design is therefore 




FACIAL SWELLING  
Facial swelling following SRM3 is due to the inflammatory response triggered by the 
surgical trauma and influenced by patients’ characteristics, preoperative difficulty 
index and intraoperative factors (90). Various techniques and methods have 
previously been used to monitor and measure facial swelling following SRM3 
including callipers, registration of reference points and landmarks, verbal and written 
response scales, ultrasound, photographic techniques and magnetic resonance 
imaging (91). Insufficient accuracy, sensitivity and reproducibility are well-known 
limitations of these methods, since two-dimensional assessment of a 3D volumetric 
alteration are characterised by inadequate facial depth and shape measurements 
(92,93). However, 3D imaging technique has made it possible to conduct accurate 
volumetric measurements of soft tissue alteration following SRM3 (92,93).  
Modern concepts of 3D scanning technology seem to be a cheap, valid and reliable 
tool for quantitative analysis of facial morphology as well as assessment of volumetric 
facial changes over time (94–96). However, the reliability, accuracy and 
reproducibility of 3D scanning technology for assessment of changes in the facial 
morphology at different time points are influenced by alignment errors by the observer 
as well as variations in facial expression or posture of the scanned subjects (97). 
Moreover, superimposition and measurements of volumetric changes are associated 
with inaccuracies due to changes in facial expression or head posture.  
In paper V, patients were positioned in an identical distance from the 3D optical 
scanner in an upright chair with closed mouth, relaxed facial expression and adequate 
head support. Uniform and reproducible natural head position was secured with laser 
lights to improve the accuracy, reproducibility and reliability of the method. In 
addition, two pilot studies were conducted to determine the accuracy and precision of 
the David SLS-3 3D scanner demonstrating that the David SLS-3 3D scanner was 
highly accurate, precise and reliable. Template matching technique is a simple tool 
for superimposition of 3D scans and has previously been used for identifying 
odontological differences of molars and volumetric changes after facial surgery 
(58,98). The 3D template can subsequently be deformed to the shape of each scan and 




Diminished facial swelling following administration of corticosteroids is due to its 
anti-inflammatory function including a reduction in vascular dilatation, liquid 
transudation and oedema formation (23,24). Preoperative administration of 
corticosteroids significantly diminish facial swelling compared with placebo, as 
documented in paper I (41). However, the optimal dose of corticosteroids and 
administration route for diminishing facial swelling following SRM3 were not 
clarified in the systematic review (paper I), since dissimilar fabricate of 
corticosteroids, doses and administration route were used as well as different 
observation periods and two-dimensional assessment methods (66). Moreover, 
administration of corticosteroids was often combined with dissimilar prescription of 
anti-inflammatory medication, which amplifies the effect on facial swelling and 
camouflage the precise value of corticosteroids. Further studies assessing the effect of 
corticosteroids on facial swelling should therefore include 3D scanning technology 
and identical consumption of anti-inflammatory medication before definitive 
conclusions can be provided about the beneficial use of corticosteroids on facial 
swelling following SRM3. 
 
Cryotherapy 
Diminished facial swelling following SRM3 with cryotherapy is probably due to a 
reduction in the inflammatory response caused by a vasoconstriction (88). The 
therapeutic effect of intermittent cryotherapy on facial swelling following SRM3 
seems to be improved compared with continuous cryotherapy, as documented in paper 
IV (99). However, the beneficial effect of intermittent or continuous cryotherapy on 
facial swelling compared with placebo could not be verified due to dissimilar 
application methods, duration of treatment time as well as different observation 
periods and assessment methods (78). Nevertheless, intermittent cryotherapy for 30 
minutes during 24 and 48 hours revealed a significant reduction in facial swelling 
following SRM3 compared with no cryotherapy as evaluated by two-dimensional 
techniques (45,49).  
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Paper V revealed no significant differences in facial swelling following SRM3 
with 30 minutes continuous postoperative cryotherapy on the cheek compared with 
no cryotherapy as evaluated by 3D facial surfaces and template matching technique 
after three and seven days (81). A refreezable gel pack in combination with a jaw bra 
was used as cooling device, since it is cheap, practically applicable in dental practice 
and does not interfere significantly in the patient's daily life. However, no beneficial 
therapeutic effect on facial swelling was observed with this type of cooling device, as 
documented in paper V (81). On the contrary, 45 minutes of immediate Hilotherm 
cryotherapy compared with conventional cooling compresses revealed a significant 
reduction in facial swelling as evaluated by 3D optical scanner technique, after two 
and ten days (80). Hilotherm is a water-circulating external device, where the 
temperature can be held constant during its use, which often is 15°C (74,81), whereas 
a refreezable gel pack will not have a constant temperature. On the contrary, if the 
temperature is too low, drainage of lymph nodes and cell metabolism will be 
hampered, which will cause oedema and increased facial swelling (100). The use of 
Hilotherm necessitates that the patient stays at the clinic after the treatment, which is 
inconvenient for the patient and occupies space at the clinic. Thickness of the 
subcutaneous adipose tissue may also influence the therapeutic effect of cryotherapy 
(89). The included patients in paper V were not standardised in terms of weight, face 
thickness and shape, which may have affected the study results (81). Consequently, 
further studies assessing the therapeutic effect of cryotherapy on facial swelling 
following SRM3 should therefore include a homogenous patient sample in relation to 
thickness of the subcutaneous tissue as well as 3D scanning technology and identical 
consumption of anti-inflammatory medication before definitive conclusions can be 
provided about the beneficial use of cryotherapy on facial swelling following SRM3. 
Furthermore, it is advisable that the method can be applied in dental practice and does 
not interfere significantly with the patient's everyday life. 
 
QUALITY OF LIFE 
Oral health-related QoL is defined as a subjective evaluation of the individual’s oral 
health, functional well-being, emotional well-being, expectations and satisfaction 
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with care and sense of self (101). Oral health-related QoL is influenced by age, gender, 
occlusion, present dental disease, previous dental experience, socioeconomic status, 
education, physical pain, psychological discomfort and psychological disability 
(71,102,103). Numerous validated oral health-related QoL questionnaires assessing 
illness, independent living, social relationships, physical senses and psychological 
well-being have previously been used following SRM3 demonstrating a deterioration 
in QoL (15,28,104). OHIP-14 and OHIP-49 are the most commonly used 
questionnaires designed to measure impairment of oral health-related QoL. OHIP-14 
is organised into seven conceptual dimensions including functional limitation, 
physical discomfort, psychological discomfort, physical disability, psychological 
disability, social disability and handicap. However, OHIP states the patient´s overall 
oral impairment and does not take a specific surgical intervention into account.  
 
Corticosteroids  
Diminished deterioration in QoL following administration of corticosteroids is 
probably due to lessen pain, restricted mouth opening and facial swelling (105). 
Patient-related outcome measures were not reported in any of the included studies in 
paper I (41). However, corticosteroids seems to improve QoL following SRM3 
compared with placebo (15,28).  
Paper II revealed no significant differences in immediate QoL as evaluated by 
OHIP-14 following SRM3 with different doses of methylprednisolone compared with 
placebo (87). Improved QoL have been reported following submucosal and peroral 
administration of 40mg prednisolone (approximate: 32mg methylprednisolone) 
compared with placebo (15). This result contrasts with the present study, which could 
be due to that antibiotics and ibuprofen were prescribed postoperatively, while 
ibuprofen and paracetamol were solely prescribed in the present study.  
Previous studies have shown a higher deterioration in QoL with increasing age 
(17,106). In paper II, OHIP-14 score was significantly increased with higher age after 
seven days. Gender seems not to influence immediate QoL (paper II), although a 
previous study has reported that females seem to have a higher risk of poor recovery 
and worsening in immediate QoL following SRM3 compared with males (12). 
Increased time of surgery is reported to influence QoL (106), which is in contrast to 
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results of paper II. Further studies assessing the effect of corticosteroids on QoL 
should therefore be conducted to assess whether corticosteroids prevent deterioration 
in QoL following SRM3. 
 
Cryotherapy 
Less pain, restricted mouth opening and facial swelling are probably the reasons for 
diminished deterioration in QoL following SRM3 with cryotherapy (105). The 
therapeutic effect of intermittent and continuous cryotherapy on QoL following 
SRM3 seems to be improved compared with no cryotherapy, as documented in paper 
IV (99). Significant less deterioration in QoL was seen with the use of continuous 
cryotherapy for 45 minutes and 24 hours and intermittent cryotherapy in 30 minutes 
for 24 hours (48,49,65). Though, different questionnaires were used to assess the 
effect of cryotherapy on QoL following SRM3 (2,48,49,65,78). Assessment of QoL 
is recommended to be evaluated by validated and uniform methods or questionnaires 
to improve the reliability of the results. Consequently, a uniform and comparable 
study design is thus necessary to be able to assess whether cryotherapy has an impact 
of QoL following SRM3. 
In paper V, OHIP-14 questionnaire revealed no significant differences in QoL 
between cryotherapy and no cryotherapy at any time point even after the groups were 
adjusted for age, smoking and length of surgery (81). OHIP-14 evaluates patient´s 
overall oral impairment and does not focus on a specific surgical intervention. 
Consequently, further RCTs assessing QoL following SRM3 should include 
additional self-administrated questionnaires focusing on patient´s perception of the 
surgical intervention. Furthermore, self-administrated questionnaires are also 
recommended to include an association between QoL and demographic factors, 
socioeconomic status as well as educational background.  
Different cooling devices can be used for cryotherapy. The temperature of a 
refreezable gel pack will rise during use, whereas a Hilotherm device will keep a 
constant temperature (80,104). The use of Hilotherm device has previously revealed 
significant improved QoL following SRM3 compared with no cryotherapy as 
evaluated by a questionnaire (104). However, solely ten patients were included, and 
the time period varied between 0 to 20 hours per day. Further RCTs evaluating the 
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effect of cryotherapy in QoL are needed using standardised, validated and evidence-
based questionnaires before recommendations and guidelines can be provided. 
 
HAEMATOLOGICAL PARAMETERS 
Haematological parameters are influenced by various factors, including age, gender, 
ethnicity, diet, life-style, medication, anaemia, pregnancy, smoking and intraoperative 
bleeding (107,108). Prolonged time of surgery may cause a decrease in the level of 
haemoglobin due to increased blood loss (109). However, SRM3 is usually associated 
with minor blood loss, though life-threatening haemorrhage has been reported (110).  
 
Corticosteroids 
Local or systemic administration of corticosteroid may influence the haematological 
parameters (42,111). Previous studies have demonstrated that levels of haemoglobin 
and leucocytes in peripheral blood increase in conjunction to corticosteroid therapy 
(42,111).  
Paper III revealed decreasing levels of haemoglobin and increasing levels of 
leucocytes and C-reactive protein compared with preoperative blood levels, three days 
following SRM3 (112). However, no statistically significant difference was observed 
in the haematological parameters between different doses of methylprednisolone 
compared with placebo (112). Methylprednisolone has a duration of action of 12-36 
hours and a plasma half-life time of 3-4 hours (113). Peripheral blood samples were 
therefore obtained before SRM3 and after three days, when methylprednisolone’s 
duration of action was ended, and the haematological parameters were anticipated to 
be normalised. The results of paper III show that a single dose of methylprednisolone 
does not compromise haematological parameters compared with placebo.  
Elderly patients are characterised by lower levels of haemoglobin and leucocytes 
in peripheral blood (108,113,114). In paper III, there were no significant differences 
in the level of haemoglobin or leucocytes, when the results were correlated for age. 
However, patients’ age ranged from 18 to 39 years, which might explain the reason 
for no statistical difference in the haematological parameters. However, pre- and 
postoperative peripheral blood samples revealed a significantly larger decrease in the 
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level of eosinophils with increasing age. This result is in accordance with the literature 
demonstrating that levels of eosinophils decrease with advancing age (115).  
Smoking increases the level of haemoglobin, leucocytes and C-reactive protein in 
peripheral blood compared with non-smoking (116,117). In paper III, there were no 
significant differences in the level of leucocytes between smokers and non-smokers. 
However, a significant lower level of haemoglobin and C-reactive protein was 
observed in smokers compared with non-smokers. These results seem not to be in 
accordance with previous studies, which may be due to the fact that only five low 
smokers were included in the present study (116,117). Thus, the influence of smoking 
on haematological parameters within this study may not be representative.  
 
LIMITATIONS 
A systematic review is a meticulous and structured synthesis of empirical evidence 
that consists of a predefined medical research question. Systematic reviews and meta-
analyses are considered as the best evidence for answering a definitive research 
question due to the transparency of each phase of the synthesis process that delimit 
bias. Conclusions of a systematic review represent a detailed and comprehensive 
overview of available evidence on a given topic and therefore frequently used for 
developing clinical practice guidelines and defining future research agendas. 
However, the value and strength of a systematic review is compromised by the 
selection of studies, heterogeneity among the included studies, inappropriate subgroup 
analyses, publication bias and loss of information on important outcomes due to 
predefined eligibility inclusion criteria and systematically extraction of specified data. 
Systematic reviews are frequently combined with a meta-analysis in evidence-based 
medicine to increase the strength of evidence and improved the statistical power. 
Meta-analysis is a statistical method that integrates and combine results of comparable 
studies. However, combining studies in a meta-analysis that differ substantially in 
design, outcome measures and observation period yield to no meaningful conclusions. 
The current knowledge of corticosteroid and cryotherapy to diminish postoperative 
discomfort following SRM3 were assessed in systematic reviews (paper I and IV). 
Meta-analyses were not conducted due to limited number of studies fulfilling the 
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inclusion criteria as well as various methodological confounding factors and 
heterogenicity among the included studies. Hence, conclusions drawn from the results 
of the systematic reviews should be interpreted with caution.  
Assessment of pain, restricted mouth opening, facial swelling and QoL following 
SRM3 with the use of corticosteroids or cryotherapy are influenced by patients’ 
characteristics, preoperative difficulty index, intraoperative factors, consumption of 
anti-inflammatory medication as well as the used evaluation methods (85,118). 
Consequently, paper II, III and V as well as the present dissertation contains 
considerably bias and various confounding factors, which influence the reliability of 
the study results. The proposed conclusions and clinical recommendations of the 
present dissertation should therefore be interpreted with caution due to the small 
sample size, inclusion of smokers and non-smokers, no systematically registration of 
consumption of analgesics or the applied temperature of the jaw bra as well as no 
standardisation according to uniform thickness of the subcutaneous tissue. In addition, 
socioeconomic status, educational background and level of daily physical activity 
were not registered, which significantly influence patient’s perception of recovery, 
pain, facial swelling and QoL following SRM3. 
Pain was evaluated by VAS, which is a valid and reliable tool for pain assessment. 
Alternative methods as verbal rating scale and faces pain scale-revised may contain 
additional information about pain interference and unpleasantness. Furthermore, VAS 
and OHIP-14 questionnaire were answered with no regard to time of the day or 
standardised according to time for consumption of analgesics, which could have 
influenced perception of pain and QoL.  
Peripheral blood samples were obtained at dissimilar timepoints with no regard to 
time of the day, physical activity or fasting, which might have influenced the 
haematological parameters.  
A refreezable gel pack and a jaw bra were used as cryotherapy following SRM3. 
The temperature of the gel pack as well as the thickness of the subcutaneous tissue 
were not registered, why the effect of cryotherapy could have been different among 
the included patients. Moreover, the initial temperature of the cold gel pack might 





• The optimal dose and administration route of corticosteroids for diminishing 
pain, restricted mouth opening, facial swelling and immediate QoL seems to 
be unknown. Further well-designed RCTs assessing the effect of 
corticosteroids in conjunction with SRM3 are needed before evidence-based 
clinical recommendations can be provided. 
 
• A single intramuscular administration of 20-40mg methylprednisolone in 
conjunction with SRM3 seems not to diminish pain, lessen restricted mouth 
opening or improve immediate QoL compared with placebo.  
 
• A single intramuscular administration of 20-40mg methylprednisolone does 
not seem to affect haematological parameters including haemoglobin, 
leucocytes and C-reactive protein, three days following SRM3. 
 
• There are no evidence-based recommendations for the use of postoperative 
cryotherapy following SRM3 to diminish pain, lessen restricted mouth 
opening or facial swelling and improve immediate QoL. Further well-
designed RCTs assessing the effect of cryotherapy in conjunction with 
SRM3 are needed before evidence-based clinical recommendations can be 
provided. 
 
• The therapeutic effect of 30 minutes cryotherapy following SRM3 to 
diminish pain, lessen restricted mouth opening or facial swelling and 





CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVE 
Pain, restricted mouth opening, facial swelling and deterioration of immediate QoL 
are well-known and common sequalae following SRM3. Prophylactic measurements 
including corticosteroids and cryotherapy are frequently used to diminish discomfort 
following SRM3. However, there are no evidence-based recommendations for the 
beneficial effect of these prophylactic measures including optimal fabricate and dose 
of corticosteroids, administration route as well as duration of cryotherapy and 
application method. No beneficial effect of methylprednisolone or short-term 
continuous cryotherapy on postoperative discomfort following SRM3 was revealed in 
the present thesis. Consequently, these prophylactic measurements should not be used 
routinely. However, the present thesis contains various methodological confounding 
factors as well as bias, which may have influenced the proposed conclusions. Further 
well-designed RCT assessing the effect of corticosteroids and cryotherapy on pain, 
restricted mouth opening, facial swelling and QoL following SRM3 should therefore 
involve a uniform patient sample, identical consumption of analgesics, 3D 
measurements and validated questionnaires involving socioeconomic status, 
educational background and level of daily physical activity before evidence-based 
clinical recommendations can be provided.  
Methylprednisolone has an intermediate duration of action. A single dose of 
methylprednisolone (20-40mg) injected in musculus masseter immediately prior to 
SRM3 (paper II and III) revealed no beneficial effect on postoperative discomfort 
compared with placebo following SRM3. Higher doses of methylprednisolone or 
corticosteroid with long-lasting duration of action could hypothetically have a 
beneficial effect on pain, restricted mouth opening, facial swelling and QoL. 
Moreover, prolonged treatment periods or alternative administration routes could 
tentatively diminish postoperative discomfort. However, these aspects need to be 
clarified in further studies. 
Application of long-term cryotherapy following SRM3 can be unpleasant and 
interfere with patient's daily life. Thirty minutes of postoperative continuous 
cryotherapy with a refreezable gel pack in a jaw bra was therefore used in paper V, 
since it is cheap, practically applicable in dental practice and does not interfere 
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significantly in the patient's daily life. However, no beneficial effect on postoperative 
discomfort was observed with the use of short-term cryotherapy following SRM3. 
Prolonged and/or intermittent cryotherapy as well as alternative application methods 
or other devices could theoretically have improved the therapeutic effect of 
cryotherapy. However, the therapeutic effect of cryotherapy is significantly 
influenced by patients’ characteristics, preoperative difficulty index, intraoperative 
factors including time of surgery and consumption of anti-inflammatory medication. 
Further studies assessing the therapeutic effect of cryotherapy following SRM3 
should therefore include a meticulous homogenous patient sample as well as 
standardisation of the temperature and application method to minimise bias and 
various confounding factors. 
Facial swelling following SRM3 has previously been assessed mainly by two-
dimensional measurements. However, it is problematic to obtain quantitative 
informations about a 3D facial swelling, based on two-dimensional measurements. A 
3D optical scanner and template matching technique was used in paper V for 
assessment of facial swelling following SRM3 revealing high accuracy and precision. 
Consequently, further studies assessing facial swelling following SRM3 with the use 
of corticosteroids or cryotherapy should include 3D measurements. 
No beneficial effect of corticosteroids or cryotherapy on postoperative discomfort 
following SRM3 was revealed in the present dissertation. However, new knowledge, 
scientific considerations as well as a reliable and high accurate 3D method for 
assessment of facial swelling was present. Moreover, the dissertation emphasises the 
importance of uniformity and standardisation in patient characteristics, study design, 
preoperative difficulty index, assessment methods and observation period as well as 
analysis of socioeconomic status and educational background is needed to delimit bias 
and obtain valid results, when assessing the beneficial effect of corticosteroids and 
cryotherapy on postoperative discomfort following SRM3.  
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